Model Evaluation of Post-M&A Success Metrics in the German Biopharmaceutical Industry
DOI:
https://doi.org/10.54337/jobm.v13i1.7502Abstract
Purpose: This study evaluates the success metrics of post-merger and acquisition (M&A) activities in the German biopharmaceutical industry, focusing on small- and medium-sized enterprises (SMEs). It examines how metrics such as economies of scale, economies of scope, market share, clinical success rate, and efficient allocation of personnel and resources affect post-M&A revenue.
Design/Methodology: The study uses partial least squares structural equation modeling (PLS-SEM) to analyze data from a survey of 384 biopharmaceutical SMEs in Germany. The survey targeted senior management involved in M&A processes, with the analysis assessing the reliability, convergent validity, and discriminant validity of the success metrics, and the statistical significance of the structural path coefficients.
Findings: The results indicate that efficient allocation of personnel and resources, as well as clinical success rate, significantly impact post-M&A revenue. In contrast, economies of scale, economies of scope, and market share do not significantly affect revenue. The study also emphasizes that while M&A activities can lead to operational efficiencies and cost savings through synergies, these benefits alone do not ensure revenue growth without effective resource management and innovation. Internal efficiencies and clinical outcomes are more critical than market expansion strategies.
Originality/Value: The study introduces a novel methodology for evaluating different success metrics in post-M&A performance within the biopharmaceutical industry using PLS-SEM. The combination of success metrics and their impact on post-M&A revenue is identified as a relatively unique research contribution.
References
Agrawal, A. & Jaffe, J.F. (2000). The post-merger performance puzzle. In Advances in Mergers and Acquisitions (Vol. 1, pp. 7–41). Emerald Group Publishing Limited. Retrieved from http://www.emeraldinsight.com/doi/abs/10.1016/S1479-361X%2800%2901002-4
Barclay, D., Higgins, C., & Thompson, R. (1995). The partial least squares (PLS) approach to causal modeling: Personal computer adoption and use as an illustration. Technology Studies, 2(2), 285–309.
Bergkvist, L., & Rossiter, J. R. (2007). The Predictive Validity of Multiple-Item versus Single-Item Measures of the Same Constructs. Journal of Marketing Research, 44(2), 175–184.
Biocom AG (2021). Deutsche Biotech-Branche wächst rasant. BIOCOM AG. Berlin. Retrieved from https://biocom.de/deutsche-biotech-branche-waechst-rasant/
Bohlin, N., Daley, E., & Thomson, S. (2000). Successful Post‐Merger Integration: Realizing the Synergies. Handbook of Business Strategy, 1(1), 225–231. https://doi.org/10.1108/eb060225
Brouthers, K. D., van Hastenburg, P., & van den Ven, J. (1998). If most mergers fail why are they so popular? Long Range Planning, 31(3), 347–353. doi:10.1016/S0024-6301(98)80002-2
Bruner, R. (2004). Where M&A Pays and Where It Strays: A Survey of the Research. Journal of Applied Corporate Finance, 16(4), 63–76.
Buono, A. F., & Bowditch, J. L. (1989). The human side of mergers and acquisitions: Managing collisions between people, cultures, and organizations (S. xxii, 317). Jossey-Bass.
Cassel, C., Hackl, P., & Westlund, A. H. (1999). Robustness of partial least-squares method for estimating latent variable quality structures. Journal of Applied Statistics, 26(4), 435–446. https://doi.org/10.1080/02664769922322
Chin, W. W., & Newsted, P. R. (1999). Structural Equation Modeling Analysis with Small Samples Using Partial Least Square. ResearchGate. Retrieved from https://www.researchgate.net/publication/242370645_Structural_Equation_Modeling_Analysis_with_Small_Samples_Using_Partial_Least_Square
Cockburn, I. M., & Henderson, R. M. (2001). Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. Journal of Health Economics, 20(6), 1033–1057. https://doi.org/10.1016/S0167-6296(01)00108-4
Danzon, P. M., Epstein, A., & Nicholson, S. (2007). Mergers and acquisitions in the pharmaceutical and biotech industries. Managerial & Decision Economics, 28(4/5), 307–328. doi:10.1002/mde.1343.
Datta, D. K., & Grant, J. H. (1990). Relationships Between Type of Acquisition, The Autonomy Given to the Acquired Firm, and Acquisition Success: An Empirical Analysis. Journal of Management, 16(1), 29–44. doi:10.1177/014920639001600103
DeVellis, R. F. (2012). Scale Development: Theory and Applications. SAGE Publications.
Dess, G. G., & Robinson Jr., R. B. (1984). Measuring organizational performance in the absence of objective measures: The case of the privately-held firm and conglomerate business unit. Strategic Management Journal, 5(3), 265–273. https://doi.org/10.1002/smj.4250050306
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: new estimates of drug development costs. Journal of Health Economics, 22(2), 151–185. https://doi.org/10.1016/S0167-6296(02)00126-1
DiMasi, J. A. (2001). Risks in new drug development: Approval success rates for investigational drugs. Clinical Pharmacology & Therapeutics, 69(5), 297–307. http://doi.org/10.1067/mcp.2001.115446
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1991). Cost of innovation in the pharmaceutical industry. Journal of Health Economics, 10(2), 107–142.
Divya Christopher, & Miss Arishma. (2013). Pharmaceutical Mergers and Acquisitions. International Journal of Advanced Research, 1(5), 119.
Ernst & Young (2021), 2022 EY M&A Firepower Report. Mannheim, Germany: Ernst & Young AG Wirtschaftsprüfungsgesellschaft.
Farrell, J., & Shapiro, C. (2001). Scale Economies and Synergies in Horizontal Merger Analysis. Antitrust Law Journal, 68(3), 685.
Hair, J. F., Hult, G. T. M., Ringle, C. M., & Sarstedt, M. (Ed.). (2017). A primer on partial least squares structural equation modeling (PLS-SEM) (Second edition). Los Angeles: Sage.
Haleblian, J., Devers, C. E., McNamara, G., Carpenter, M. A., & Davison, R. B. (2009). Taking Stock of What We Know About Mergers and Acquisitions: A Review and Research Agenda. Journal of Management, 35(3), 469–502. http://doi.org/10.1177/0149206308330554
Henseler, J., Ringle, C. M., & Sarstedt, M. (2014). A new criterion for assessing discriminant validity in variance-based structural equation modeling. Journal of the Academy of Marketing Science, 43(1), 115–135. https://doi.org/10.1007/s11747-014-0403-8
Heracleous, L., & Murray, J. (2001). The urge to merge in the pharmaceutical industry. European Management Journal, 19(4), 430–437. doi:10.1016/S0263-2373(01)00046-9
Heracleous, L., & Murray, J. (2001). The urge to merge in the pharmaceutical industry. European Management Journal, 19(4), 430–437. doi:10.1016/S0263-2373(01)00046-9
King, D. R., Dalton, D. R., Daily, C. M., & Covin, J. G. (2004). Meta-analyses of post-acquisition performance: indications of unidentified moderators. Strategic Management Journal, 25(2), 187–200. doi:10.1002/smj.371
King, D., Slotegraaf, R., & Kesner, I. (2008). Performance implications of firm resource interactions in the acquisition of R&D-intensive firms. Organization Science. Retrieved from http://epublications.marquette.edu/mgmt_fac/23
Kola, I., & Landis, J. (2004). Opinion: Can the pharmaceutical industry reduce attrition rates? Nature Reviews. Drug Discovery, 3(8), 711–5. http://doi.org/http://dx.doi.org.ezproxy.csu.edu.au/10.1038/nrd1470
Kumar, D., & Gupta, S. (2023). Effective Strategies for Launching and Increasing the Sales of a New Drug. 8(4).
Kurdas, C. (1998). Dynamic Economies of Scope in the Pharmaceutical Industry. Industrial and Corporate Change, 7(3), 501–521. http://doi.org/10.1093/icc/7.3.501
LaMattina, J. L. (2011). The impact of mergers on pharmaceutical R&D. Nat Rev Drug Discov, 10(8), 559–560. http://doi.org/10.1038/nrd3514
Larsson, R., & Finkelstein, S. (1999). Integrating Strategic, Organizational, and Human Resource Perspectives on Mergers and Acquisitions: A Case Survey of Synergy Realization. Organization Science, 10(1), 1–26.
Leschik, D., Rossberger, R., & Oczkowski, E. (2020). M&As in Germany: Measuring success for the pharma and biotech industries. Journal of Business Strategy https://doi.org/10.1108/JBS-07-2020-0153
McIntosh, C. N., Edwards, J. R., & Antonakis, J. (2014). Reflections on Partial Least Squares Path Modeling. Organizational Research Methods, 17(2), 210–251. https://doi.org/10.1177/1094428114529165
Mitchell, M. L., & Mulherin, J. H. (1996). The impact of industry shocks on takeover and restructuring activity. Journal of Financial Economics, 41(2), 193–229. doi:10.1016/0304-405X(95)00860-H
Montgomery, C. A., & Wilson, V. A. (1986). Research note and communication mergers that last: A predictable pattern? Strategic Management Journal, 7(1), 91–96. http://doi.org/10.1002/smj.4250070108
Papadakis, V. M., & Thanos, I. C. (2010). Measuring the Performance of Acquisitions: An Empirical Investigation Using Multiple Criteria. Measuring the Performance of Acquisitions. British Journal of Management, 21(4), 859–873.
Papadakis, Vassilis M. (2005). The role of broader context and the communication program in merger and acquisition implementation success. Management Decision, 43(2), 236–255. https://doi.org/10.1108/00251740510581948
Pautler, P. A. (2003). Evidence on mergers and acquisitions. Antitrust Bulletin, 48(1), 119.
Pavlou, A. K., & Reichert, J. M. (2004). Recombinant protein therapeutics-success rates, market trends and values to 2010. Nature Biotechnology, 22(12), 1513–1519. http://doi.org/10.1038/nbt1204-1513
Pervaaz, V. (2010). M&A in the Pharma Industry. Applied Clinical Trials, 19(11), 36,38.
Pilloff, S. J. (1996). Performance Changes and Shareholder Wealth Creation Associated with Mergers of Publicly Traded Banking Institutions (SSRN Scholarly Paper No. ID 7529). Rochester, NY: Social Science Research Network. Retrieved from http://papers.ssrn.com/abstract=7529
Powell, W. W., & Brantley, P. (1992). Competitive cooperation in biotechnology: Learning through networks?’
Ranft, A. L., & Lord, M. D. (2000). Acquiring new knowledge: The role of retaining human capital in acquisitions of high-tech firms. The Journal of High Technology Management Research, 11(2), 295–319. https://doi.org/10.1016/S1047-8310(00)00034-1
Ravenscraft, D. J., & Scherer, F. M. (1987). Mergers, sell-offs, and economic efficiency. Washington, D.C: Brookings Institution.
Ringle, Christian M., Wende, Sven, & Becker, Jan-Michael. (2022). SmartPLS 4. Oststeinbek: SmartPLS. Retrieved from https://www.smartpls.com
Schweizer, L. (2002). The key drivers and success factors for M&A strategies in the biotechnological and pharmaceutical industrym{1}. Pharmaceuticals Policy & Law, 5(1), 41.
Schweizer, L. (2005). Organizational Integration of Acquired Biotechnology Companies into Pharmaceutical Companies: The Need for a Hybrid Approach. The Academy of Management Journal, 48(6), 1051–1074.
Schweizer, L. (2009). Post-merger Integration of International Biotechnology Start-Ups: The Relationship between Entrepreneurial Strategy, Culture and Human Resources. Zeitschrift für Betriebswirtschaft, ZfB-Special Issue International Entrepreneurship, 61/1: 133-53
Schweizer, L. (2012). Characteristics of Biotechnology Mergers and Acquisitions. In D. Faulkner, S. Teerikangas, & R. J. Joseph (Eds.), The Handbook of Mergers and Acquisitions (pp. 638–658). Oxford University Press. Retrieved from http://www.oxfordscholarship.com/view/10.1093/acprof:oso/9780199601462.001.0001/acprof-9780199601462-chapter-26
Sharma, D. S., & Ho, J. (2002). The Impact of Acquisitions on Operating Performance: Some Australian Evidence. Journal of Business Finance & Accounting, 29(1-2), 155–200. http://doi.org/10.1111/1468-5957.00428
Sirower, M. L. (1997). The Synergy Trap: How Companies Lose the Acquisition Game. Simon and Schuster.
Thanos, I. C., & Papadakis, V. M. (2012). Unbundling acquisition performance : how do they perform and how can this be measured? Oxford Univ. Press
Walsh, G. (2003). Biopharmaceuticals : biochemistry and biotechnology (2nd ed.). New York: J. Wiley.
Downloads
Published
Issue
Section
License
Articles published in Journal of Business Models follow the license Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND 3.0)
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License: Attribution - NonCommercial - NoDerivs (by-nc-nd). Further information about Creative Commons
